Evidence map›Paper›PMID 24297499›Full record

ArticleJournal of neurovirology2013

Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.

Huichao Chen, David B Clifford, Lijuan Deng, Kunling Wu, Anthony J Lee, Ronald J Bosch, Sharon A Riddler, Ronald J Ellis, Scott R Evans

Abstract read
In one paragraph

Article in Journal of neurovirology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. HIV-associated painful neuropathy: where are we?Arquivos de neuro-psiquiatria · 2022
    Article
  7. Article
  8. Review
  9. HIV-related Neuropathy: Pathophysiology, Treatment and Challenges.Journal of neurology and experimental neuroscience · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Dissociable Contributions of Precuneus and Cerebellum to Subjective and Objective Neuropathy in HIV.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huichao ChenHarvard School of Public Health, 651 Huntington Avenue, FXB-607, Boston, MA, 02115, USA, hchen@sdac.harvard.edu.
David B Clifford
Lijuan Deng
Kunling Wu
Anthony J Lee
Ronald J Bosch
Sharon A Riddler
Ronald J Ellis
Scott R Evans

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
NEUROLOGIC AIDS RESEARCH CONSORTIUMU01NS032228 · NINDS · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 2003 to 2008
$11.4M
NIMODIPINE AND MEMANTINE FOR THE NEUROLOGICAL MANIFESTATIONS OF HIV-1R01NS032228 · NINDS · WASHINGTON UNIVERSITY · PI CLIFFORD, DAVID B · 1997 to 2001
$2.7M
NIAID NIH HHS AI068636NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069494NIMH NIH HHS P30 MH062512NINDS NIH HHS NS32228NINDS NIH HHS R01 NS032228NINDS NIH HHS U01 NS032228PHS HHS 1 U01 068634
6 · The paper itself

Abstract

Peripheral neuropathy (PN) is a common neurological complication of HIV infection that has debilitating effects on quality of life. While there has been a comprehensive evaluation of the prevalence of neuropathic signs/symptoms and risk factors (RFs) for PN or symptomatic PN (SPN) with initiation of combination antiretroviral therapy (cART) in ART-naïve patients, similar evaluation in ART-experienced patients is limited. This study investigated the prevalence and RFs for PN/SPN in ART-experienced patients enrolled in clinical salvage therapy studies. Between February 2000 and June 2007, 522 ART-experienced participants who experienced virologic failure with a prior regimen and started new regimens were followed longitudinally and annually screened for signs and symptoms of PN. Rates of PN/SPN at 3 years since parent study entry were 52.8 and 24.0 %, respectively. Aging, taller height, protease inhibitor use, and female sex were significant RFs for PN/SPN. The use of statin drugs was significantly associated with lower odds of SPN, and it may prevent progression from no SPN to SPN.

Indexed as

HIV-1AdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDrug Therapy, CombinationFemaleHIV InfectionsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedOdds RatioPeripheral Nervous System DiseasesPrevalenceRisk FactorsAnti-HIV AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID24297499
PMCPMC3965352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.